CN1863803A - 嘧啶衍生物 - Google Patents

嘧啶衍生物 Download PDF

Info

Publication number
CN1863803A
CN1863803A CNA028195817A CN02819581A CN1863803A CN 1863803 A CN1863803 A CN 1863803A CN A028195817 A CNA028195817 A CN A028195817A CN 02819581 A CN02819581 A CN 02819581A CN 1863803 A CN1863803 A CN 1863803A
Authority
CN
China
Prior art keywords
compound
group
mixture
solvate
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028195817A
Other languages
English (en)
Chinese (zh)
Inventor
H·－M·埃根维勒
M·鲍姆加斯
P·舍林
N·贝尔
M·克里斯塔德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1863803A publication Critical patent/CN1863803A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA028195817A 2001-10-04 2002-09-05 嘧啶衍生物 Pending CN1863803A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10148883.1 2001-10-04
DE10148883A DE10148883A1 (de) 2001-10-04 2001-10-04 Pyrimidinderivate

Publications (1)

Publication Number Publication Date
CN1863803A true CN1863803A (zh) 2006-11-15

Family

ID=7701322

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028195817A Pending CN1863803A (zh) 2001-10-04 2002-09-05 嘧啶衍生物

Country Status (16)

Country Link
US (1) US7312224B2 (https=)
EP (1) EP1432715B1 (https=)
JP (1) JP4782376B2 (https=)
KR (1) KR20040041166A (https=)
CN (1) CN1863803A (https=)
AT (1) ATE389655T1 (https=)
AU (1) AU2002362806B2 (https=)
BR (1) BR0213037A (https=)
CA (1) CA2462799C (https=)
DE (2) DE10148883A1 (https=)
ES (1) ES2303564T3 (https=)
HU (1) HUP0401654A3 (https=)
PL (1) PL369819A1 (https=)
RU (1) RU2004114239A (https=)
WO (1) WO2003031447A2 (https=)
ZA (1) ZA200403334B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928241A (zh) * 2015-12-29 2017-07-07 中山大学 一种4‑取代胺基‑6‑甲氧羰基苯并呋喃并[2,3‑d]嘧啶类化合物及制备和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005061171A1 (de) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
DE102005061170A1 (de) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
DE102007027800A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007027799A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) * 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
US20130065936A1 (en) * 2010-05-14 2013-03-14 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
AU2011281015B2 (en) 2010-07-23 2015-09-24 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
CA2861464C (en) 2012-01-25 2018-03-06 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
EP3194399B1 (en) 2014-09-17 2019-04-10 Pécsi Tudományegyetem New agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
CN108137614B (zh) * 2015-12-02 2021-01-05 深圳市塔吉瑞生物医药有限公司 一种稠合嘧啶化合物及包含该化合物的组合物及其用途
RU2625316C1 (ru) * 2016-04-13 2017-07-13 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) 2-АМИНОЗАМЕЩЕННЫЕ 6-МЕТОКСИ-4-ТРИФТОРМЕТИЛ-9Н-ПИРИМИДО[4,5b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ПРЕДШЕСТВЕННИКИ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) * 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
JPS5542999B2 (https=) * 1972-02-14 1980-11-04
CH592668A5 (https=) 1973-10-02 1977-10-31 Delalande Sa
ZA815765B (en) * 1980-08-22 1983-04-27 Du Pont Herbicidal sulfonamides
US4487626A (en) 1980-08-22 1984-12-11 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
EP0514540B1 (en) 1989-09-19 1996-07-17 Teijin Limited PYRROLO 2,3-d]PYRIMIDINE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL PREPARATION COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT
JP2562520B2 (ja) * 1989-09-19 1996-12-11 帝人株式会社 ピロロ〔２，３ーｄ〕ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
DE19752952A1 (de) 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
YU76100A (sh) 1998-06-02 2003-12-31 Osi Pharmaceuticals Inc. Pirolo(2,3-d) pirimidin preparati i njihova primena
DE19942474A1 (de) 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
DE19944604A1 (de) 1999-09-17 2001-03-22 Merck Patent Gmbh Aminderivate
KR100840727B1 (ko) 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
AP1893A (en) 2000-12-01 2008-09-23 Osi Pharm Inc Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928241A (zh) * 2015-12-29 2017-07-07 中山大学 一种4‑取代胺基‑6‑甲氧羰基苯并呋喃并[2,3‑d]嘧啶类化合物及制备和应用
CN106928241B (zh) * 2015-12-29 2020-02-14 中山大学 一种4-取代胺基-6-甲氧羰基苯并呋喃并[2,3-d]嘧啶类化合物及制备和应用

Also Published As

Publication number Publication date
AU2002362806B2 (en) 2008-09-18
RU2004114239A (ru) 2005-10-27
US7312224B2 (en) 2007-12-25
CA2462799A1 (en) 2003-04-17
WO2003031447A3 (de) 2003-08-28
ES2303564T3 (es) 2008-08-16
WO2003031447A2 (de) 2003-04-17
EP1432715A2 (de) 2004-06-30
HUP0401654A2 (hu) 2004-11-29
DE50211929D1 (en) 2008-04-30
BR0213037A (pt) 2004-10-05
EP1432715B1 (de) 2008-03-19
US20040242595A1 (en) 2004-12-02
PL369819A1 (en) 2005-05-02
DE10148883A1 (de) 2003-04-10
JP2005504847A (ja) 2005-02-17
JP4782376B2 (ja) 2011-09-28
HUP0401654A3 (en) 2006-02-28
KR20040041166A (ko) 2004-05-14
ZA200403334B (en) 2006-05-31
ATE389655T1 (de) 2008-04-15
CA2462799C (en) 2010-11-02

Similar Documents

Publication Publication Date Title
CN1110493C (zh) 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
CN1255403C (zh) 用作磷酸二酯酶抑制剂的β－咔啉衍生物
CN1297555C (zh) Mcp－1功能的拮抗物及其使用方法
CN1863803A (zh) 嘧啶衍生物
CN101031561A (zh) 可以用作凝血因子xa抑制剂的羰基化合物
CN1310921C (zh) 双环氧代吡啶和氧代嘧啶衍生物
CN1184208C (zh) 取代的苯并咪唑及其制备和用途
CN101048412A (zh) 哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
CN1161341C (zh) cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
CN1138780C (zh) 噻吩并嘧啶类
CN1481244A (zh) 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
HK1040712A1 (en) Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
CN1575191A (zh) 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病
CN1777612A (zh) 新的哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
CN1272107A (zh) 作为因子Xa抑制剂的苄脒衍生物
CN1809351A (zh) Akt活性抑制剂
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1518541A (zh) 苯基衍生物
CN1674893A (zh) 苯并咪唑衍生物
CN1474693A (zh) 噻吩并嘧啶的应用
CN1106663A (zh) 噻吩并嘧啶衍生物及其制备方法和用途
CN1642927A (zh) 环状酰胺
CN1483035A (zh) 氨磺酰基噻吩并嘧啶
CN1771249A (zh) 作为凝血因子Xa抑制剂用于治疗血栓形成的1－N－苯基－2－N－苯基吡咯烷－1,2－二甲酰胺衍生物
CN85108120A (zh) 三环吡啶衍生物的制备及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication